Arca
Skip to content
Tools
Tools

ENV: Envelope glycoprotein gp160

Protein in Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1) that 4 drugs act on.

  • Drugs that act on it: 4
  • Approved: 1
  • In phases 1 to 3: 3
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on ENV, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Other 3

Approved1

  • Fostemsavir

Phase 30

    Phase 20

      Phase 13

      • AD-439
      • F105
      • KD-247

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • The Chemo-Sero-Therapeutic Research Institute125%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Envelope polyprotein GP160 inhibitor.
      FostemsavirApprovedViiV HealthcareSmall moleculeInhibitor7
      AD-439Phase 1—OtherInhibitor0
      F105Phase 1—OtherInhibitor0
      KD-247Phase 1The Chemo-Sero-Therapeutic Research InstituteOtherInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 7 in all, from ClinicalTrials.gov.
      A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentFostemsavirPhase 3RecruitingViiV HealthcareFeb 6, 2026
      A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIVFostemsavirPhase 1Active, not recruitingViiV HealthcareJul 8, 2025
      Reducing Systemic Inflammation in People on Antiretroviral TherapyFostemsavirPhase 2RecruitingCentre hospitalier de l'Université de Montréal (CHUM)Jun 22, 2025
      Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)FostemsavirPhase 2 / Phase 3Active, not recruitingGilead SciencesAug 16, 2022
      Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER StudyFostemsavirPhase 4Active, not recruitingOrlando Immunology CenterFeb 2, 2022
      Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral ResistanceFostemsavirPhase 1 / Phase 2Active, not recruitingPENTA FoundationDec 1, 2020
      Attachment Inhibitor Comparison in Heavily Treatment Experienced PatientsFostemsavirPhase 3Active, not recruitingViiV HealthcareFeb 13, 2015

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3520, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.